MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Impulse Control Disorders

A. Espay, K. Markopoulou, I. Zhang, E. Pappert, B. Navia (Cincinnati, USA)

Meeting: MDS Virtual Congress 2021

Abstract Number: 383

Keywords: Apomorphine, Parkinsonism, Pharmacotherapy

Category: Parkinson’s Disease: Clinical Trials

Objective: Assess impact of apomorphine sublingual film (APL) on impulse control disorders (ICDs) in patients with Parkinson’s disease (PD) and “OFF” episodes.

Background: In a 12-wk pivotal study, APL was efficacious and generally well tolerated for on-demand treatment of “OFF” episodes in patients with PD. However, dopaminergic agents have been associated with ICDs.

Method: An ongoing, open-label, Phase 3 study (NCT02542696) to evaluate the long-term safety (LTS) and efficacy of APL enrolled patients with PD (new or rollover from prior Phase 2/3 studies) and “OFF” episodes on stable PD medications. APL dose titration occurred in patients who were “OFF” to determine the effective and tolerable dose (10–35 mg; 5-mg increments) that converted them to FULL “ON” within 45 min. In the LTS phase, patients self-administered their titrated APL dose for up to 5 “OFF” episodes/d. ICDs were assessed using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease – Rating Scale (QUIP-RS). Results were summarized descriptively and assessed at wks 24, 36, and 48. TEAEs associated with ICDs were also evaluated.

Results: This analysis (data cut 30Sep2020) evaluated 397 patients (median [range] exposure to APL was 169 [1–1181] d; 1.8 mean doses/d; highest dose received in the LTS phase, 10/15/20/25/30/35 mg: 18%/23%/23%/18%/11%/7%). In the LTS phase, mean (SD) baseline total ICD score was 5.4 (6.61) and changes from baseline were –0.2 (6.29), –0.5 (8.15), and –0.5 (7.54) at wks 24, 36, and 48, respectively. Mean (SD) baseline total QUIP-RS score was 10.0 (11.96) and changes from baseline were –1.7 (11.76), –2.9 (15.28), and –2.0 (16.53) at wks 24, 36, and 48, respectively. The incidence of individual ICD behaviors decreased or remained similar from screening to wk 48: gambling (14% vs 16%), sex (47% vs 34%), buying (40% vs 30%), eating (54% vs 37%), hobbyism/punding (53% vs 37%), and medication use (41% vs 34%). TEAEs associated with ICDs were infrequent during the LTS phase and occurred in <1% of patients, consistent with a prior safety analysis in 459 unique patients with PD who received ≥1 dose of APL where TEAEs of gambling and impulsive behavior each occurred at 0.2%.

Conclusion: The repeated and chronic use of apomorphine sublingual film as an on-demand treatment for “OFF” episodes in patients with PD had minimal impact on ICDs over a period of up to 48 wks in the long-term study.

To cite this abstract in AMA style:

A. Espay, K. Markopoulou, I. Zhang, E. Pappert, B. Navia. Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Impulse Control Disorders [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/apomorphine-sublingual-film-for-off-episodes-in-parkinsons-disease-impact-on-impulse-control-disorders/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/apomorphine-sublingual-film-for-off-episodes-in-parkinsons-disease-impact-on-impulse-control-disorders/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley